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Abstract
Here we report an integrated analysis that leverages data from treatment of genetic mouse models
of prostate cancer along with clinical data from patients to elucidate new mechanisms of castration
resistance. We show that castration counteracts tumor progression in a Pten-loss driven mouse
model of prostate cancer through the induction of apoptosis and proliferation block. Conversely,
this response is bypassed upon deletion of either Trp53 or Lrf together with Pten, leading to the
development of castration resistant prostate cancer (CRPC). Mechanistically, the integrated
acquisition of data from mouse models and patients identifies the expression patterns of XAF1-
XIAP/SRD5A1 as a predictive and actionable signature for CRPC. Importantly, we show that
combined inhibition of XIAP, SRD5A1, and AR pathways overcomes castration resistance. Thus,
our co-clinical approach facilitates stratification of patients and the development of tailored and
innovative therapeutic treatments.
We conceived the co-clinical platform as an innovative approach to improve the design,
speed and outcomes of rational and personalized clinical treatments1. The power of this
approach lies in harnessing data gained from pre-clinical studies performed in several
genetic mouse models and combining it with the concurrent investigation of therapies, either
conventional or experimental, in human patients.
One goal of this approach is to expedite the identification of key genetic and molecular
determinants that dictate resistance to a specific therapy in order to facilitate the
stratification of human candidates for enrollment in treatment with different therapies,
optimize combination treatments and accelerate new drug approval.
In this study we have implemented this paradigm in an investigation of androgen deprivation
therapy (ADT), which is a widely-prescribed standard-of-care therapy for prostate cancer.
Although almost invariably effective in the short term, ADT is consistently followed by the
development of castration resistant prostate cancer (CRPC) in the majority of patients2.
Given the diverse genetic alterations reported to drive prostate cancer initiation and
progression, we hypothesized that these same genetic alterations also govern the tumor
response to ADT, and may be utilized to develop novel combinational treatments.
Testing this hypothesis with the co-clinical approach led to the discovery of new pathways
underlying ADT resistance, as well as new potential modalities for overcoming this serious
therapeutic hurdle.
RESULTS
Prostate cancer genetic dictates androgen deprivation response
PTEN, LRF, and TP53 loss or mutation has been associated with prostate cancer progression
in human and mouse models (Supplementary Table 1)4-12. We therefore enrolled prostate
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conditional Pten null mice (Ptenflox/flox;Probasin-Cre), Pten and Lrf double null mice
(Ptenflox/flox;Lrfflox/flox;Probasin-Cre), and Pten and p53 double null mice
(Ptenflox/flox;p53flox/flox;Probasin-Cre) to test the hypothesis that advanced prostate cancer
with distinct genetic makeups respond differentially to ADT. For each genetically-distinct
tumor type, we generated cohorts of 15 mutant mice that were castrated at the age at which
they had developed prostate cancer (high grade-prostatic epithelial neoplasia (HG-PIN)
characterized by focal invasive carcinoma) as previously reported4,5,13. Age-matched non-
castrated cohorts were used as controls. All cohorts were monitored for 3 months post-
castration.
Groups of 5 mice from each cohort (castrated and non-castrated) were sacrificed at 1, 2 and
3 months post-castration for histopathological analysis (see Fig. 1a for timeline of the
analysis). Mice from the 3-month post-castration group were also imaged by magnetic
resonance imaging (MRI) for tumor volume assessment on a monthly schedule (Fig. 1a).
Histopathological analysis of Ptenflox/flox;Probasin-Cre mice at 1 and 2 months post-
castration identified the presence of a significant amount of normal epithelium in castrated
mice, indicative of a clear response to castration, when compared to the levels of normal
epithelium in the non-castrated control group [1 month: PI 0 = 25% vs 0 < 5%, (p < 0.01) in
Supplementary Fig. 1a left panel and 2 months: PI 0 = 40% vs. 0 < 5%, (p < 0.01) Fig. 1b
left panels and Supplementary Fig. 1a]. Importantly, and in agreement with a previous
report14, examination of the DLP from castrated Ptenflox/flox;Probasin-Cre mice at 3 months
post-castration demonstrated a strong reduction of normal epithelium, indicating onset of
acquired resistance to ADT (Fig. 1c left panel and Supplementary Fig. 1a). In sharp
contrast to this finding, we did not observe any response in DLP from either castrated
Ptenflox/flox;Lrfflox/flox;Probasin-Cre (Fig. 1b-c center panels and Supplementary Fig. 1a)
or Ptenflox/flox;p53flox/flox;Probasin-Cre mutants (Fig. 1b-c right panels and Supplementary
Fig. 1a). These results indicate that loss of either p53 or Lrf in a Pten-null genetic context
confers a de novo resistance to androgen deprivation in the DLP tumors.
Interestingly, and in line with recent publications15, examination of the ventral lobe of the
mouse prostate (VP) from castrated Ptenflox/flox;Probasin-Cre mice identified, an intrinsic
propensity of the tumors derived from this lobe to be resistant to ADT (PI 0 = 0%;
Supplementary Fig. 1b).
The anterior lobe of the mouse prostate (AP) of Ptenflox/flox;Probasin-Cre,
Ptenflox/flox;Lrfflox/flox;Probasin-Cre, Ptenflox/flox;p53flox/flox;Probasin-Cre mice are
characterized by a marked cystic dilation of prostate ducts5, a feature preventing accurate
pathological evaluation of the extent and severity of tumor lesions. Therefore, to assess ADT
responses in this lobe, we quantitated the tumor volume of AP lesions by MRI (Fig. 1d). In
line with the results described for the DLP above, we observed that castration of
Ptenflox/flox;Probasin-Cre led to reduced tumor volumes (Fig. 1d upper panels), while no
regression was observed in castrated Ptenflox/flox;Lrfflox/flox;Probasin-Cre (Fig. 1d middle
panels) and Ptenflox/flox;p53flox/flox;Probasin-Cre mice (Fig. 1d lower panels).
In accordance with the results obtained through physical castration, Ptenflox/flox;Probasin-
Cre mice displayed sensitivity (as previously described)16 while
Ptenflox/flox;Lrfflox/flox;Probasin-Cre and Ptenflox/flox;p53flox/flox;Probasin-Cre mice
displayed resistance to chemical castration (bicalutamide), thereby validating that resistance
to ADT is tumor-intrinsic and not dependent on the specific treatment (Supplementary Fig.
1c-f).
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Together, these data demonstrate that Pten-null prostate cancer is initially sensitive to
androgen deprivation, yet invariably acquires castration-resistance. In contrast, our analysis
clearly demonstrates that both Pten;Lrf and Pten;p53 double null prostate cancers display
complete resistance to castration.
Genetic determinants of ADT response in human patients
We next determined whether the differential response to castration we observed in the
different mouse models would allow us to predict responses to ADT in human prostate
cancer (Fig. 2a). To this end, we constructed a tissue microarray (TMA) designed to
interrogate ADT response biomarkers by immunohistochemistry (IHC). The TMA included
84 biopsied specimens from prostatectomized human primary prostate cancer (Gleason
Score 6/7) that had been treated with neo-adjuvant ADT and showed variable response to
the treatment, as measured by the ratio in circulating prostate specific antigen (PSA) levels
before and after ADT, proliferation rate and percentage of cells with nuclear AR localization
(Fig. 2b, Supplementary Fig. 2a-c, Supplementary Table 2 and Supplementary Note). We
also performed an additional analysis to validate our stratification criteria. It has been
previously reported that levels of 10 ng/ml of PSA at diagnosis are frequently predictive of
worse prognosis when compared with patients with levels below 10 ng/ml [reviewed in
Ref.17,18]. 31 of our patients (out of 84) had a PSA value higher than 10 ng/ml before
treatment with ADT in neo-adjuvant setting (Supplementary Fig. 2c). After 3 months on
ADT, patients have now been classified as either good (16 patients) or poor responders (15
patients) based on the ratio of PSA levels after and before treatment (Supplementary Fig.
2c). Importantly, all the patients that retained levels of PSA > 10 ng/ml post-ADT belonged
to the category of poor responder (11 out of 15) and none was found among the 16 good
responders (p=1.612E-05; Supplementary Fig. 2c). Finally, we obtained and analyzed the
follow-up information of 36 of the 84 patients originally enrolled in this study. Notably,
only 2 out of 23 patients classified as “Good Responders” have developed resistance to
ADT, while a consistent 6 out of 13 belong to the category of the “Poor Responders”
(p=0.01; Supplementary Fig. 2d). These data further suggest the notion that the category
that we have identified as poor responder represents the group of patients most likely to
develop tumor recurrence and castration-resistant distant metastasis [reviewed in Ref.17,18].
As mentioned, TP53 loss or mutation has been associated with tumor progression in a subset
of human patients (Supplementary Table 1)6-11. Taking into account that p53 loss cannot
be evaluated by IHC, as the protein levels are usually extremely low, on our TMA we could
only assess mutational events, which would result in p53 overexpression. Mutation in p53
has been reported to correlate with progression to higher Gleason Scores (4 + 3 or 4 + 4) and
CRPC6, while the patients in our TMA had lower Gleason Scores (mainly 3 + 3 and 3 + 4 as
detailed in the Supplementary Table 2). In agreement with these findings, in these earlier
prostate cancer lesions from our cohort we could not identify any sample with a
homogeneously elevated p53 immunohistochemical staining. We therefore interrogated a
pre-existing array-based comparative genomic hybridization (aCGH) database made up of
37 human prostate cancer metastases (28 out of 37 were castration resistant)11. 43% of these
castration resistant metastatic patients (12 of 28) presented heterozygous loss and 7%
homozygous loss (2 out of 28) of p53, thereby confirming the relevance of loss in this tumor
suppressor gene in CRPC.
We next focused our attention on PTEN and LRF and performed IHC on our low-Gleason
TMAs (Fig. 2c-d). In this analysis, we observed no difference in the mean PTEN loss in
those patients who responded poorly or favorably to ADT (Fig. 2c). In contrast, patient
tumors harboring a significantly larger mean number of LRF-null cells stratified as poor
responders to ADT (Fig. 2d). Additionally, the number of patients that displayed both
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PTEN- and LRF-protein loss was 15 out of 84 total samples, 4 in the category of good
responders (4/48 patients, 8.7%) and 11 in the category of poor responders (11/36 patients,
30.5%) (Fig. 2e, p=0.0132), suggesting that concomitant loss of PTEN and LRF stratifies
for poor responsiveness to castration.
In order to mirror in humans the data obtained in genetic mouse models, we sought to assess
in prostate cancer patients whether concomitant genetic loss of LRF with PTEN may be a
stronger indicator of CRPC development than loss of PTEN only. To this end, we
interrogated again the aCGH database made up of 37 human prostate cancer metastases (28
out of 37 were castration resistant)11. We identified 336 genes undergoing genetic losses
solely in castration-resistant specimens characterized by concomitant loss of PTEN in at
least 80% of cases (Supplementary Fig. 2e and Supplementary Table 3). Intriguingly, 110
of these genes were located on the telomeric p arm of chromosome 19 (Supplementary Fig.
2e) including LRF gene (Zbtb7a) (Fig. 2f). This suggests that in humans, as predicted by our
mouse study, there is a functional association between loss of PTEN and genetic deletion of
LRF for CRPC development (Fig. 2g and Supplementary Fig. 2f).
The relevance of LRF loss in CRPC was further confirmed by the analysis of two other large
pre-existing aCGH datasets made up of 58 and 50 human castration resistant metastatic
prostate cancer samples19,20. LRF was found to be genetically lost in 26% of cases (15 out
of 58), and in 33% of cases (15 out of 50) respectively19,20. In particular, 10 castration
resistant metastatic specimens out of 15 (67%) in the first dataset19 and 8 out of 15 (53%) in
the second dataset20 showed specific deletion of the telomeric p arm of chromosome 19
which contains the LRF gene (Zbtb7a) (Fig. 2h, and Supplementary Fig. 2g). Of note, in
the dataset recently published by Grasso and colleagues20, 2 out of 3 described castration
resistant bone marrow metastases show deletion of the telomeric p arm of chromosome 19
(WA48, and WA51), while the remaining one (WA23) is characterized by a somatic
missense mutation (K60R) in the BTB/POZ domain of LRF, a fundamental region for its
transcriptional repressive activity21.
Finally, a similar result was also obtained by the analysis of the expression profile data set
from Tomlins et al.22, where we observed a significant reduction in LRF expression in
castration resistant metastases (20) from several organs (Fig. 2i), thereby further
corroborating a role for LRF loss in resistance to ADT.
Together, these data show that prostate cancers characterized by distinct genetic background
differentially respond to ADT in mice as well as human patients, and that LRF represents an
unexpected player in the response of prostate cancer to androgen deprivation.
Biological responses to androgen deprivation
Castration typically results in a major decrease in prostatic mass, with the key molecular
hallmarks including decreased proliferation and increased apoptosis23. Accordingly, we
examined whether the absence of androgen differentially affects the proliferative index of
these tumor types. To this end, we performed IHC on the VP, DLP, and AP of castrated
mice utilizing the cellular proliferation marker Ki67. In Ptenflox/flox;Probasin-Cre mice we
observed at one month post-castration a significant reduction in the overall proliferative
index (Fig. 3a and 3b for quantifications, left panels). In contrast, we observed no
difference in the proliferative index in any prostate lobes from either
Ptenflox/flox;Lrfflox/flox;Probasin-Cre mice (Fig. 3a and 3b for quantifications, center
panels), or Ptenflox/flox;p53flox/flox;Probasin-Cre (Fig. 3a and 3b for quantifications, right
panels) at one month post-castration compared to non-castrated controls. These findings
suggest that Lrf or p53 deletion in Pten-null prostate epithelium confers an ability to
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proliferate in conditions of androgen depletion. Notably, no difference in Ki67 staining was
observed in the VP of the same mice (Supplementary Fig. 3a).
We next measured the induction of apoptosis in the prostatic epithelium of castrated
Ptenflox/flox;Probasin-Cre, Ptenflox/flox;Lrfflox/flox;Probasin-Cre, and
Ptenflox/flox;p53flox/flox;Probasin-Cre mice. The induction of an early apoptotic response was
observed in all lobes of the prostate and in all genotypes, as analyzed by measuring
elevation of caspase-3 cleavage (Fig. 3c). In contrast, Parp cleavage and pyknotic nuclei
(Supplementary Fig. 3b), feature of terminal apoptosis, were observed in all prostate lobes
of castrated Ptenflox/flox;Probasin-Cre mice (Fig. 3c), but were completely absent in all lobes
of Ptenflox/flox;Lrfflox/flox;Probasin-Cre, and Ptenflox/flox;p53flox/flox;Probasin-Cre castrated
mice, indicating apoptotic inhibition in these tumors.
We next investigated the effects of androgen withdrawal on androgen receptor (AR)
localization in our different prostate cancer genotypes. AR was predominantly translocated
to the cytoplasm in all genotypes shortly after castration, as expected in the absence of
androgen24 (Fig. 3d for DLP and AP, Supplementary Fig. 3c for VP). However,
quantitative IHC analysis of prostates from castrated Ptenflox/flox;Lrfflox/flox;Probasin-Cre,
and Ptenflox/flox;p53flox/flox;Probasin-Cre mice identified a modest but significantly greater
number of cells with nuclear AR compared to the prostates of castrated
Ptenflox/flox;Probasin-Cre mice (Fig. 3e and relevant quantification), suggesting that cells
switch to or harbor pre-existing alternative pathways of AR activation in Pten;Lrf or
Pten;p53 double null CRPC (see below).
In summary, these data suggest that Pten;Lrf or Pten;p53 double null tumor prostatic cells,
in contrast to Pten-null only, posses the ability to sustain androgen-independent
proliferation, while escaping the engagement of an apoptotic response.
XAF1 and SRD5A1 are key biomarkers for ADT response in mouse and human
Next we sought to identify the molecular mechanisms underlying the differential sensitivity
displayed by Ptenflox/flox;Probasin-Cre vs. Ptenflox/flox;Lrfflox/flox;Probasin-Cre and
Ptenflox/flox;p53flox/flox;Probasin-Cre double null prostate tumor cells when challenged by
androgen deprivation. For this purpose, we interrogated microarray gene expression profiles
from mouse prostate specimens4. Strikingly, we observed a significant down-regulation
(p=1.07E-12) of X-linked inhibitor of apoptosis protein-associated factor-1 (Xaf1; Fig. 4a)
in Ptenflox/flox;Lrfflox/flox;Probasin-Cre mice compared to Ptenflox/flox;Probasin-Cre. XAF1
was first identified as a protein that binds and opposes the anti-caspase activity of X-linked
inhibitor of apoptosis (XIAP), thereby promoting apoptosis25. A growing body of evidence
has also demonstrated strong involvement of the XAF1-XIAP pathway in cell cycle
regulation through yet unknown mechanisms26-32. The down-regulation of Xaf1 was
confirmed by qRT-PCR, IHC and Western blot in specimens from
Ptenflox/flox;Lrfflox/flox;Probasin-Cre mice (Fig. 4b-d). Since XAF1 has been recently
reported to be a p53-responsive gene33, we assessed Xaf1 levels in
Ptenflox/flox;p53flox/flox;Probasin-Cre mice. As expected, Xaf1 was significantly down-
regulated in Ptenflox/flox;p53flox/flox;Probasin-Cre prostates as measured by qRT-PCR, IHC
and Western blot (Fig. 4b-d). Interestingly, IHC of Xaf1 in DLP from castrated
Ptenflox/flox;Probasin-Cre mice analyzed 90 days post-castration showed reduced levels of
staining-positive cells compared to ones analyzed 30 days post-castration, supporting the
concept of Xaf1 as a good biomarker for castration resistance (Supplementary Fig. 4a).
Further interrogation of expression profiles of Ptenflox/flox;Lrfflox/flox;Probasin-Cre murine
prostates identified a significant up-regulation of 3-oxo-5-alpha-steroid 4-dehydrogenase 1
(Srd5a1) gene compared to Ptenflox/flox;Probasin-Cre mice (Fig. 4a). Srd5a1 and Srd5a2
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enzymes catalyze the conversion of testosterone into dihydrotestosterone (DHT), a more
potent and stable form of testosterone, and Srd5a1 is known to be frequently up-regulated in
human CRPC35. Production of DHT represents an important alternative mechanism that
allows activation of AR at castration-levels of androgen35. qRT-PCR on the prostates from
Ptenflox/flox;Lrfflox/flox;Probasin-Cre andPtenflox/flox;p53flox/flox;Probasin-Cre mice
confirmed Srd5a1 up-regulation compared to Ptenflox/flox;Probasin-Cre prostate cancer (Fig.
4e), while no changes in the level of Srd5a2 transcript were observed (Supplementary Fig.
5a). Interestingly, qRT-PCR analysis in DLP from castration resistant Ptenflox/flox;Probasin-
Cre mice analyzed 90 days post-castration also showed higher levels of Srd5a1 compared to
the castration sensitive Ptenflox/flox;Probasin-Cre prostates analyzed 30 days post-castration,
whereas only a mild increase was observed in the level of Srd5a2 (Supplementary Fig. 4b).
Notably, while Western blot analysis of AR in DLP from castrated Ptenflox/flox;Probasin-Cre
mice analyzed 90 days post-castration showed no differences in the levels of the protein
compared to ones analyzed 30 days post-castration (Supplementary Fig. 4a), IHC analysis
showed different localization of AR in the two different contexts. In the castration sensitive
setting (30 days after castration) AR, as expected, was mainly localized in the cytoplasm. In
contrast, AR was found to be nuclear 90 days post castration in large areas of the
Ptenflox/flox;Probasin-Cre mutant tumor, as frequently observed in human prostate cancers
that have acquired resistance to ADT34, and Western blot analysis showed higher levels of
the AR transcriptional target Probasin (Supplementary Fig. 4a).
In order to translate the relevance of biomarkers found in the mouse to the human context,
we assessed the status of XAF1 and SRD5A1 pathways in human prostate cancer. For this,
we performed IHC with anti-XAF1 on the custom TMA mentioned above (Fig. 4f), and
quantitated the number of cells that had down-regulation of XAF1 (Fig 4f, right panel). In
this analysis, we observed that XAF1 protein levels are lower in human prostate cancer and
XAF1 staining is significantly lost in those patients that respond poorly to ADT (Fig. 4f).
Furthermore, we analyzed the expression of XAF1/XIAP and SRD5A1 mRNA in several
human prostate cancer expression arrays (Fig. 4g-l)11,36-39. Importantly, we observed that
the expression levels of XAF1 are significantly decreased, in contrast to XIAP and
SRD5A1, which were significantly increased, in the patients with the most aggressive
prostate cancer, as characterized by Gleason Score, recurrence and metastasis (Fig. 4g-l).
This data, combined with the results obtained in an androgen deprivation setting, suggests
that down-regulation of XAF1 and up-regulation of SRD5A1 in high Gleason Score prostate
cancer and metastasis might be predictive of poor sensitivity to ADT.
XIAP inhibition sensitizes castration resistant prostate cancers to ADT
Our findings suggest a potential therapeutic modality based on the combination of ADT with
a XIAP inhibitor for CRPC. Therefore, we treated the AR-mutant/DHT-sensitive LnCaP
C4-2 and the AR-null/DHT-insensitive DU145 and PC3 cell lines with the plant-derived
XIAP inhibitor embelin32 and ADT [charcoal/dextran treated steroid-free FBS (SFM)] as
single agents and in combination (Supplementary Fig. 6a-d). While single treatments with
SFM or embelin at a concentration of 5 μM for 4 days did not induce any apoptosis, the
combination of embelin and SFM triggered a clear increase in the apoptotic response in
LnCaP C4-2 cells, as measured by PARP cleavage (Supplementary Fig. 6a). Notably, the
combination of embelin with SFM and MDV3100 (an experimental androgen receptor
antagonist drug developed for the treatment of castration-resistant prostate cancer currently
in Phase III clinical trial) strikingly increased the apoptotic response in LnCaP C4-2
castration resistant cell line (Supplementary Fig. 6a). Likewise XIAP silencing induced
apoptosis in SFM conditions (Supplementary Fig. 6b), confirming the fundamental role of
XAF1/XIAP pathway in human CRPC. As expected, the AR-null DU145 and PC3 prostate
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cancer cell lines displayed de novo resistance to the SFM-plus-embelin combination
treatment since SFM (mimicking ADT) is unable to trigger any apoptotic response in these
cell lines (Supplementary Fig. 6c-d). Conversely, in these cells ionizing radiation (IR)
synergizes with embelin by triggering apoptosis40.
To corroborate our in vitro results in vivo, we next enrolled our castration-resistant
Ptenflox/flox;Lrfflox/flox;Probasin-Cre and Ptenflox/flox;p53flox/flox;Probasin-Cre mouse models
in treatment programs with embelin and ADT. Specifically, we treated 4 month-old
Ptenflox/flox;Lrfflox/flox;Probasin-Cre and 3 month-old Ptenflox/flox;p53flox/flox;Probasin-
Cremice with bicalutamide (Casodex) or embelin alone and in combination. Remarkably,
while both Ptenflox/flox;Lrfflox/flox;Probasin-Cre and Ptenflox/flox;p53flox/flox;Probasin-Cre
prostate cancers exhibited resistance to bicalutamide or embelin treatment as single agents
(Supplementary Fig. 7a-b), all prostate lobes showed a marked tumor regression when
treated with bicalutamide in combination with embelin (Fig. 5a and Supplementary Fig.
7a-b). Specifically, we found that treatment ofPtenflox/flox;Lrfflox/flox;Probasin-Cre and
Ptenflox/flox;p53flox/flox;Probasin-Cre prostate cancers with bicalutamide plus embelin was
characterized by a profound reduction in the proliferation rate (Fig. 5b-e), which in the case
of Ptenflox/flox;Lrfflox/flox;Probasin-Cre prostate cancers was also accompanied by the rescue
of the apoptotic response (Fig. 5f-g and Supplementary Fig. 7c-d).
These findings clearly demonstrate that castration-resistant prostate tumors characterized by
the impairment of the XAF1/XIAP pathway become sensitive to ADT when treated with the
XIAP inhibitor embelin.
Combination of ADT, embelin and dutasteride for the treatment of CRPC
We hypothesized that management of CRPC could further benefit from the addition of an
SRD5A1 inhibitor to the combination therapy with embelin and ADT. Importantly, the
SRD5A1 inhibitor dutasteride is currently utilized in clinical trials in combination with ADT
for the treatment of advanced prostate cancer (see URLs)41-43.
At first, therefore, we treated the VCaP, LnCaP and 22RV1 human prostate cell lines with
embelin, dutasteride and ADT as single agents and in triple combination. Strikingly, the
triple combination of embelin plus dutasteride and SFM induced an even more potent
apoptotic response compared to each of the double combinations, embelin plus SFM and
dutasteride plus SFM (Fig. 6a-d and Supplementary 6e-f).
We next treated castration resistant 4 month-old Ptenflox/flox;Lrfflox/flox;Probasin-Cre and 3
month-old Ptenflox/flox;p53flox/flox;Probasin-Cre mice with ADT in combination with
embelin and dutasteride. Both Pten;Lrf and Pten;p53 double-null prostate cancers exhibited
a further significant decrease in tumor burden after the triple treatment with bicalutamide,
embelin, and dutasteride when compared to the treatment with the dual combination
bicalutamide plus embelin (Fig. 6e).
These findings clearly demonstrate that castration-resistant prostate tumors characterized by
the impairment of the XAF1/XIAP and SRD5A1 pathways are sensitized to ADT when
treated with embelin and dutasteride, thereby rendering this triple combination an effective
novel therapeutic approach to the treatment of XAF1/XIAP/SRD5A1 genetically stratified
CRPC patients.
DISCUSSION
Our data support the hypothesis that the response to ADT is dictated by the genetic make-up
of prostate cancer. Our findings argue that genetic mouse models can be extremely valuable
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in tailoring the administration of standard-of-care treatments on the basis of genetic and
molecular stratification.
We find that Pten-loss driven prostate cancer exhibits an overall reduction in tumor volume
in response to castration, indicating that this genetic mouse model is initially sensitive to
androgen deprivation. Nevertheless, the mice demonstrate a rapid recurrence of prostate
cancer at 3 months post-castration. CRPC development in Pten-null prostate cancer appears
to be accompanied by concomitant down-regulation of Xaf1, up-regulation of Srd5a1, and
re-localization of AR in the nucleus (Supplementary Fig. 4a).
This model of “acquired” resistance is consistent with the initial response patterns and
invariable latent resistance observed in human prostate cancer subjects. Importantly, we
have now shown that concomitant Pten and either Lrf or p53 deletions abrogate the response
of Pten-null tumors to ADT.
Lrf- and p53-loss associated castration resistant prostate cancers exhibit low levels of Xaf1,
a phenomenon which potentially explains the lack of both apoptosis induction and
proliferation arrest. The importance of this pathway is further highlighted by the observation
that XIAP is highly up-regulated during prostate cancer progression and CRPC both in
human44 and mice (Supplementary Fig. 5b). Accordingly, we have shown that the XIAP
inhibitor embelin, when combined with ADT, potently suppresses tumor growth in vitro,
confirming what previously reported45, and in vivo in our castration resistant genetic mouse
models.
We also found that Pten;Lrf and Pten;p53 double null CRPCs, as well as Pten null CRPC,
are characterized by the up-regulation of Srd5a135, and, importantly, that dutasteride
(SRD5A1 inhibitor) further increases prostate tumor response to embelin plus ADT.
We think our integrated mouse and human analysis has identified potential new therapeutic
strategies. Patients with prostate cancer characterized by XAF1-XIAP/SRD5A1
deregulations are likely to quickly develop CRPC, thus ADT in such patients should be
combined with embelin and dutasteride (Supplementary Fig. 7e).
In sum, our study demonstrates the validity of a cross-species integrated genetic approach to
the evaluation of prostate cancer therapies. A particularly powerful aspect of the approach is
the combined access it affords to data regarding genetic and molecular differences between
tumors whether in human patients or mouse models. Importantly, this study has led to the
identification of critical pathways and genetic alterations dictating responses to standard-of-
care therapeutic modalities, as well as novel “druggable” biomarkers for overcoming
resistance to such treatments. This approach can be customized for any tumor types when
appropriate genetic mouse models are available, and for testing of experimental targeted
therapies1,46. Thus the applications of an integrated approach to the field of human cancer
therapy are clearly significant, and potentially transformative.
URLs
ClinicalTrial.gov: http://www.clinicaltrials.gov
Taylor et al., 2010: http://www.cbioportal.org/public-portal/index.do?
cancer_study_id=mskcc_prad
Grasso et al., 2012: http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE35988
Tomlins et al., 2007: http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE6099
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Liu et al., 2009: http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE14996
Bioconductor simpleaffy package: http://www.bioconductor.org/
METHODS
Pten, p53 and Lrf mouse models
Previously generated Ptenflox/flox, p53flox/flox and Lrfflox/flox mice5,13,47 were crossed with
the Probasin-Cre mice48 for the deletion of Pten, p53 and Lrf specifically in the prostate
epithelium. The pathological index (PI) we used was as follows: 0 (normal tissue), 1 (glands
with a monolayer of epithelial cells with evident cellular neoplastic features), 2 (HG-PIN
characterized by glands with more than 50% of cell-free lumen) to 3 (HG-PIN characterized
by glands with less than 50% of cell-free lumen). Number of animals per genotype per
experiment was estimated accordingly to the error variance. Mice were randomized and all
the mouse work performed blindly to the genotype of the mice and in accordance with our
IACUC approved protocol. For genotyping, tail DNA was subjected to PCR following the
protocols previously described5,13,47.
Western blot, immunohistochemistry and proliferation analysis on human and mouse
prostate tissue
Cell lysates were prepared with RIPA buffer [1 X PBS, 1% Nonidet P40, 0.5% sodium
deoxycholate, 0.1% SDS and protease inhibitor cocktail (Roche)] and cleaned by
centrifugation. The following antibodies were used for Western blot analysis: mouse anti-
cleaved Parp D214 (mouse specific), rabbit anti-Parp 46D11, rabbit anti-cleaved Caspase 3
(Asp175), rabbit anti-Gapdh 14C10, rabbit anti-XIAP 3B6 (Cell signaling), rabbit anti-AR
PG-21 (Millipore), rabbit anti-Xaf1 SAB2900401 (Sigma), IMG-379 (Imgenex), goat anti-
Probasin sc17126 (Santa Cruz). For immunohistochemistry, prostate tissues were fixed in
10% neutral-buffered formalin (Sigma) overnight, subsequently washed once with PBS,
transferred into 50% ethanol and stored in 70% ethanol. Prostate lobes were embedded in
paraffin, sectioned and stained with hematoxylin and eosin (H&E) in accordance with
standard procedures. Sections were stained with the following antibodies: rabbit anti-Ki-67
(Novacastra), rabbit anti-AR (Millipore), rabbit anti-Xaf1 (Sigma), rabbit anti cleaved
Caspase3 (Cell Signaling). Proliferative cells were identified by positive Ki-67 staining. A
total of 5000 cells were counted from 50 different fields for each section for each lobe. The
analysis was repeated on three different mice for each genotype.
MRI analysis
Mouse prostate images were acquired on an ASPECT Model M2 1T tabletop MRI scanner
(ASPECT Magnet Technologies Ltd., Netanya, Israel). The M2 is a permanent magnet with
zero magnetic fringe field. All mice were placed in the supplied 35mm mouse RF coil,
calibrated to a RF frequency of between 43-45 MHz which is used for both transmission and
reception. Prior to acquisition, mice were anesthetized with a mixture of isoflurane and
oxygen via an external vaporizer at a percentage of 2.0 and 1.5%, respectively. Percentages
were adjusted as needed during MR acquisition, as respiration was monitored using a small
animal physiological monitoring system (BIOPAC Systems, Inc., Aero Camino Goleta,
California). Scout images were acquired using a GRE steady state sequence to acquire
images in all three orthogonal planes/orientations. For prostate imaging, mice were
positioned in the center of the magnet with bladder used as the anatomical reference for the
center point. Axial T2 weighted SE images were first acquired with the following
parameters: FOV 40 × 40 mm, 1/0 mm thickness/gap, TR/TE of 4600/40 ms, 256 × 256
matrix, 2 NEX, and a dwell time of 30 μs. Subsequent to the T2 weighted scan, a T1 SE
sequence was also acquired by simply changing the TR/TE values to 625/10 ms and
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decreasing the dwell to 16μs. The NRG Console GUI performs online reconstruction which
then allows data to be converted into DICOM files and archived for export into any image
analysis software. Tumor volume quantification was performed as previously described49.
Quantitative RT-PCR
Total RNA was prepared from mice frozen tissues using the Trizol method (Invitrogen).
cDNA was obtained with iScriptTM cDNA Synthesis Kit (Bio-Rad). Triplicate samples for
quantitative PCR were run in the Lightcycler 480 (Roche) using the SYBR Green I Master
(Roche). Each value was adjusted by using Gapdh levels as reference (see Supplementary
Table 4 for primer sequences).
Human mRNA profiling and aCGH analysis
CGH array data for 37 metastatic samples, yet pre-processed with RAE algorithm, were
downloaded by GEO database (see URLs)11. CGH array data for 50 metastatic samples, pre-
processed with RAE algorithm, were downloaded from GEO database (see URLs)20. Data
for 13 EPI and 20 Metastatic patient samples analyzed on a spotted cDNA platform were
obtained from GEO database (see URLs)22. 58 metastatic samples data were downloaded
from GEO database and analyzed by Affymetrix Genome-Wide human single nucleotide
polymorphism Array 6.0 (see URLs)19. MAS5 algorithm, as implemented in Bioconductor
simpleaffy package (see URLs), was used to normalize raw data and Affymetrix annotation
na31 to annotate probe-set ID to the corresponding Entrez Gene ID. Differential expression
and statistical significance have been evaluated by Bioconductor limma package (see
URLs). P-value lower than 0.05 were considered significant.
Patient samples
This study was performed after approval of the Institutional Review Board of the Dana-
Farber Cancer Institute and Brigham and Women's Hospital, Boston, MA. Archival paraffin-
embedded tissue blocks of prostate cancer from patients were retrieved from the
Departments of Pathology from Beth Israel Deaconess Medical Center, Boston, and from
the University of Ancona, Italy.
Tissue microarray construction, immunohistochemistry and image analysis
Among men in the study cohort, we obtained archival formalin-fixed, paraffin-embedded
radical prostatectomy samples (n=87; all study subjects). The study pathologists (R.L.,
M.L.) reviewed H&E slides of each FFPE tissue block to select areas of tumor and benign
tissue for construction of a tissue microarray (TMA). The TMA was constructed by taking
three 0.6-mm cores of tumor tissue and two 0.6-mm cores of benign tissue per case from a
formalin-fixed, primary tumor nodule and transferring each core to a recipient block. The
tumor and benign specimens from all 87 cases were included on two different TMAs. We
characterized the expression profile of PTEN, and LRF in tumors included on the TMAs by
immunohistochemical evaluation of protein expression for each, using a BioGenex i6000
automated staining platform (BioGenex Laboratories Inc., Fremont CA). TMA sections
were cut at 4μm, and subsequently deparaffinized in xylene, followed by a graded alcohol
rehydration. Antigen retrieval was performed by microwaving the tissue in citrate buffer
(LRF), or EDTA buffer (PTEN) for 5 minutes. Antisera for PTEN (Cell Signaling
Technologies, Beverly, MA) and LRF (Novus Biologicals, Littleton, CO) were then applied
(PTEN: 1/200 overnight; LRF: 1/500 for 1 hour). Primary antibody detection was performed
using a polymer-HRP detection kit (Biogenix) with visualization achieved using a
commercially available chromogenic DAB kit (Vector Laboratories Inc., Burlingame, CA).
Finally, sections were counterstained with hematoxylin, and dehydrated in a graded series of
alcohols prior to the application of a coverslip. TMA slides stained with either PTEN or
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LRF were scanned using the CRi Vectra 200-slide scanning platform (v1.4.1, CRi/Caliper,
Hopkinton, MA) following a standard bright-field scanning protocol. For each tumor core
represented on the TMA, the system acquired images at 20nm intervals and combined them
into a stack file that represents one image. To detect both DAB and hematoxylin, a
maximum likelihood method was used to extract each spectrum, which represents each
element of the IHC profile. The analysis of each core image stack was performed using
InForm (v1.3, CRi/Caliper). To do this, a training set comprising two classes of tissue was
created: ‘tumor’ and ‘other’. Representative areas for each class were marked on 16-20
images from the TMA. Using the hematoxylin and DAB spectra, InForm was trained to
differentiate between the two classes. Within the training set, InForm's ability to correctly
differentiate tumor from other was determined by a trained pathologist (R.T.L), and the
process was repeated until further training of InForm correctly identified all tumor tissue.
IHC images were then analyzed using InForm's ‘object-based’ algorithm. The multispectral
imaging profile obtained with the Vectra scanner allows the software to segment the nucleus
and cytoplasm using the unmixed spectra of the nuclear counterstain and the DAB
immunohistochemical stain used for each biomarker. To quantify the nuclear staining for
each biomarker, the following parameters were employed: auto scale and fill hole were
enabled, and the area was set to 0.15. For percentage analyses, a nuclear threshold for each
biomarker was set as follows: PTEN was 0.288; LRF was 0.08. For cytoplasmic staining,
the following parameters were set: the inner distance to nuclei was 0, the outer distance to
nuclei was 7, the minimum size (pixel) was 1, and the threshold was 0.56. For percentage
analyses, a cytoplasmic threshold for each biomarker was set as follows: PTEN was 0.066,
LRF was 0.056. For each core, the DAB intensity of each biomarker for each cell is the
determined by InForm. With a threshold applied, InForm calculated the percentage of cells
that were positive for each biomarker in the nucleus, in the cytoplasm, and in both
compartments. TMA cores that were difficult to classify due to technical limitations
(complications with tissue presentation or core loss) were removed from all analyses. For
the current analysis, of the 87 cases represented on the two TMA, three were removed from
the analysis due to insufficient representation on the TMA (core loss). For all data metrics
obtained, tissue samples were reviewed by a trained pathologist (R.T. L. and M.L.) to ensure
appropriate assignment of scores.
In vitro treatments
VCaP, LnCaP, LnCaP C4-2, 22Rv1, PC3, and DU145 human prostate cancer cells were
purchased from the ATCC, cultured in DMEM or RPMI medium (as indicated by the
ATCC) supplemented with 10% FBS and tested for mycoplasma contamination every
month. For androgen deprivation and drug treatments, the regular medium plus 10% FBS
was replaced with regular medium supplemented with 10% charcoal/dextran treated FBS
(Hyclone) (Steroid Free Medium) and 10 μM dutasteride, and/or 10 μM MDV3100, and/or
5μM embelin for 2 or 4 days. For siRNA experiments, cells were transfected with XIAP
siRNA (obtained from Dharmacon) and 72 hrs after transfection, the regular medium plus
10% FBS was replaced with regular medium supplemented with 10% charcoal/dextran
treated FBS (Hyclone) (Steroid Free Medium). For western blotting, cells were lysed in Ripa
buffer (50 mM Tris pH 8.0, 150 mM NaCl, 1% NP-40, 0.5% deoxycholic acid, and 0.1%
SDS) supplemented with protease inhibitors (Complete; Roche), briefly sonicated, and
resolved on SDS-PAGE gels. The proteins were transferred to nitrocellulose membranes and
detected by chemiluminescence after incubation with antibodies against PARP (1:1000, Cell
Signaling), XIAP (1:1000, Cell Signaling), AR (1:1000, Millipore), Actin (1:4000, Sigma),
GAPDH (Cell Signaling), and LRF (13E9).
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In vivo treatments
Chemical castration studies in mice were conducted with bicalutamide (Casodex) at a dose
of 10 mg/kg by oral gavage, daily for 5 days a week for 4 weeks. Tumor-bearing mice were
treated with a combination of bicalutamide (10 mg/kg) plus XIAP inhibitor embelin (60 mg/
kg) in 0.1% carboxymethyl cellulose (CMC) (as vehicle) by oral gavage, daily for 5 days a
week for 4 weeks. Triple treatment experiments were conducted with bicalutamide (10 mg/
kg) plus XIAP inhibitor embelin (60 mg/kg) in 0.1% carboxymethyl cellulose (CMC) (as
vehicle) by oral gavage, 3 days a week and bicalutamide (10 mg/kg) plus Srd5a1 inhibitor
dutasteride (XY mg/kg) in 0.1% carboxymethyl cellulose (CMC) (as vehicle) by oral
gavage, 2 days a week for 4 weeks. Mice were euthanized and tumors were dissected,
weighed, and processed for histopathology and molecular analyses at the conclusion of these
studies.
Statistical Analysis—Results are expressed as mean ± SD. Comparisons between groups
were assessed using Student's t-Test analysis. P ≤ 0.05 was considered significant.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Editorial Summary (PF)
Pier Paolo Pandolfi and colleagues report that compound loss of Pten with Lrf or Trp53
leads to de novo resistance to androgen deprivation therapy in prostate cancer. Integrative
analysis of mouse and patient data in a co-clinical approach identified XIAP and
SRD5A1 inhibitors as potential therapies for castration-resistant prostate cancer.
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Figure 1. Prostate tumors characterized by distinct genetic alterations differentially respond to
castration
(a) Timeline of analysis of Ptenflox/flox;Probasin(Pb)-Cre,
Ptenflox/flox;Lrfflox/flox;Probasin(Pb)-Cre, and Ptenflox/flox;p53flox/flox;Probasin(Pb)-Cre
noncastrated (n=15) and castrated (n=15) cohorts of mice. (b-c) Quantification of percentage
area of normal epithelium in the prostate of Ptenflox/flox;Probasin(Pb)-Cre (left),
Ptenflox/flox;Lrfflox/flox;Probasin(Pb)-Cre (middle), and Ptenflox/flox;p53flox/flox;Probasin(Pb)-
Cre (right) castrated and non-castrated mice at 60 (b) and 90 (c) days post-castration.
Representative images of H&E staining of DLP from castrated and non-castrated mice of the
indicated genotypes are shown. (d) Representative MRI images of prostate cancers (Anterior
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Lobe AP) in castrated and non-castrated mice of indicated genotype 4 days before and 60
days post-castration. Tumor volume (area outlined in red) was quantified as described in the
experimental procedures. Asterisk represents the location of the bladder.
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Figure 2. Analysis of human prostate cancer unveils the relevance of LRF loss in the response to
androgen deprivation
(a) Cross-species integrated genetic screenings (b) Histogram showing the percentage of
PSA-reduction following treatment used to stratify patients as good responders (yellow) or
poor responders (blue) to ADT. Mean value of percentage of PSA reduction distribution is
shown (dashed line). (c-d) PTEN and LRF IHC in human prostate cancer TMAs. The
percentage of tumor cells with loss of PTEN and LRF were measured. Patients were
considered good responders (0) or poor responders (1) to ADT according to the percentage
of PSA reduction. Arrows highlight PTEN and LRF null cells. (e) Percentage of patients that
experienced combined loss of PTEN and LRF in the category of good (8.7%) and poor
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responders (30.5%). This distribution resulted statistically significant p=0.0132 in a Fisher
test. (f) Schematic representation of the deletion of the p arm on chromosome 19 (green) in
human CRPC. ZBTB7a genetic locus is indicated (arrow). (g) Diagram showing the
distribution of PTEN-loss (orange) and LRF-loss (white) genetic alterations in castrated
(blue) and noncastrated (green) metastasis. (h) CGH array data for 58 castration resistant
prostate cancer metastatic samples shows genetic loss of the telomeric region of
chromosome 19 containing the Zbtb7a locus. Data were processed by Partek Genomic Suite
6.4 Segmentation Algorithm (deletions are shown in green on the left side, amplification are
showed in red on the right side). (i) Expression profile analysis of human castration resistant
metastases shows statistically significant down-regulation of LRF expression.
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Figure 3. Differential responses to castration in different genetic backgrounds
(a-b) IHC staining of DLP and AP from castrated and non-castrated mice at 30 days post-
castration. Upper panel: Ki-67 staining on prostate sections from castrated and noncastrated
mice of indicated genotype. Lower panel: quantification of Ki-67 staining. Quantification
has been performed as described in the methods. For each genotype, castrated (n=3, grey
bar) and non-castrated (n=3, black bar) mice were analyzed. Percentage of Ki67 positive
cells in DLP and AP prostate lobes was evaluated on a total of 15,000 cells per lobe. Data
are presented as mean ± standard deviation. (c) Western blot analysis on VP, DLP and AP
from castrated Ptenflox/flox;Probasin(Pb)-Cre, Ptenflox/flox;Lrfflox/flox;Probasin(Pb)-Cre and
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Ptenflox/flox;p53flox/flox;Probasin(Pb)-Cre mice. Western blot analyses were performed on
sample lysates collected from mice sacrificed 4 days after castration. (d) IHC staining of AR
on DLP and AP from castrated and noncastrated mice sacrificed 30 days after castration. (e)
Quantification of cells with nuclear AR localization in castrated Ptenflox/flox;Probasin(Pb)-
Cre (light grey bar), Ptenflox/flox;Lrfflox/flox;Probasin(Pb)-Cre (dark grey bar) and
Ptenflox/flox;p53flox/flox;Probasin(Pb)-Cre (black bar) prostate tumors. Number of cells with
nuclear AR staining in DLP and AP prostate lobes was evaluated in n=3 castrated mice/
genotype on a total of 2,500 cells for each prostate lobe. Data are presented as mean ±
standard deviation.
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Figure 4. Deregulation of XAF1 and SRD5A1 levels dictates prostate cancer progression and
castration resistance in mouse and human
(a) Analysis of the expression profiles of Ptenflox/flox;Lrfflox/flox;Probasin(Pb)-Cre versus
Ptenflox/flox;Probasin(Pb)-Cre prostates shows a significant down-regulation of Xaf1 and a
concomitant up-regulation of Srd5a1. (b) Quantitative RT-PCR of Xaf1 in VP (n=3, black
bars), DLP (n=3, dark grey bars) and AP (n=3, light grey bars) samples collected from
Ptenflox/flox;Probasin(Pb)-Cre, Ptenflox/flox;Lrfflox/flox;Probasin(Pb)-Cre, and
Ptenflox/flox;p53flox/flox;Probasin(Pb)-Cre mice. Data are presented as mean ± standard
deviation. (c) IHC with anti-Xaf1 of the same samples in b. (d) Western blot analysis on the
same samples in b. (e) Quantitative RT-PCR for Srd5a1 in VP (n=3, black bars), DLP (n=3,
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dark grey bars) and AP (n=3, light grey bars) samples collected from WT,
Ptenflox/flox;Probasin(Pb)-Cre, Ptenflox/flox;Lrfflox/flox;Probasin(Pb)-Cre and
Ptenflox/flox;p53flox/flox;Probasin(Pb)-Cre mouse prostates. Data are presented as mean ±
standard deviation. (f) XAF1 staining and relative quantification in human prostate cancer
TMA. (g) LRF and XAF1 down regulation and SRD5A1 induction in castration resistant
prostate cancer xenografts (orange bars) versus castration sensitive (black bars). (h-l) XAF1,
XIAP, and SRD5A1 expression levels in primary and metastatic prostate cancer compared
to normal prostatic epithelium.
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Figure 5. Synergistic effect of ADT and embelin, in mouse CRPC
(a) Weight of VP, DLP, and AP of Ptenflox/flox;Lrfflox/flox;Probasin(Pb)-Cre and
Ptenflox/flox;p53flox/flox;Probasin(Pb)-Cre mice treated with bicalutamide (Casodex) (n=8)
(black bars) or bicalutamide plus embelin (n=8) (grey bars) for 4 weeks. Data are presented
as mean ± standard deviation. (b-e) Proliferation rate analysis as percentage of Ki67 positive
cells in VP, DLP, and AP of the samples described in a. Data are presented as mean ±
standard deviation. (f-g) H&E and apoptosis analysis through Western blot quantification of
Parp cleavage versus total Parp in VP, DLP, and AP of the
Ptenflox/flox;Lrfflox/flox;Probasin(Pb)-Cre prostate cancers described in a.
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Figure 6. Genetic and molecular assessments in mice and patients dictate new experimental
treatment to overcome CRPC
(a-d) Apoptosis analysis in human prostate cancer cell line (VCaP) treated with ADT, XIAP
inhibitor (embelin), or SRD5A1 inhibitor (dutasteride), as single agent or in combination.
Quantifications of PARP cleavage versus total PARP after 2 days of treatment are shown.
(e) Weight of VP, DLP, and AP of castration resistant Ptenflox/flox;Lrfflox/flox;Probasin(Pb)-
Cre and Ptenflox/flox;p53flox/flox;Probasin(Pb)-Cre mice treated with bicalutamide (Casodex)
(n=4/genotype, black bars), bicalutamide plus embelin (n=4/genotype, dark grey bars), or
bicalutamide plus embelin plus dutasteride (n=4/genotype, light grey bars) for 4 weeks. Data
are presented as mean ± standard deviation.
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